If you’re currently on a compounded version of semaglutide or tirzepatide, you’ve probably already seen the headlines about the FDA’s proposal to exclude these drugs from bulk compounding, and the wave of warning letters hitting telehealth companies. What most of that coverage skips is the actually useful part: what should you, specifically, do about it right now. Not the policy analysis — the checklist. Here it is.
First, understand what’s actually changing and why
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the “503B Bulks List,” the list of ingredients outsourcing facilities are legally allowed to compound from raw bulk substances. The agency’s position is that bulk compounding was only ever justified by drug shortages, and with FDA-approved versions now more widely available, that legal justification has largely expired — regardless of the price gap between compounded and brand-name product. FDA Commissioner Marty Makary was explicit about that distinction: “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” specifically ruling out cost as a qualifying reason under the statute.
Alongside that, the FDA has separately sent warning letters to telehealth companies over marketing claims — specifically, websites implying compounded product is identical to brand-name drugs or has gone through the same clinical trials, which isn’t true and isn’t legal to claim. None of this means compounded GLP-1s are being banned overnight, or that everyone currently on one is in immediate danger. It means the rules are actively tightening, the legal pathway that allowed a lot of current supply to exist is narrowing, and it’s worth getting ahead of that instead of finding out the hard way when a refill doesn’t come through.
Step one: find out exactly what you’re actually taking
This sounds obvious, but a surprising number of patients on compounded GLP-1s can’t answer it precisely. Ask your pharmacy directly: is this the standard base compound (semaglutide or tirzepatide in its approved molecular form), or a modified salt form? Stanford Medicine pharmacist Michael Blyumin flagged one especially common red flag directly: “Nobody legitimate makes sublingual semaglutide. I’ve never seen data that says how efficiently it’s absorbed that way.” If your product is a sublingual drop, a dissolving tablet, or contains additives like B12 mixed into the same vial, that’s worth a direct conversation with your prescriber, since these formulations haven’t been through the same safety review as standard compounded product, let alone the FDA-approved brand-name drugs.
Step two: verify your pharmacy’s actual registration status
Compounding pharmacies operate under one of two very different regulatory categories: 503A pharmacies compound for individual patients based on a specific prescription, under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under federal FDA oversight — and it’s specifically 503B bulk compounding of these three drugs that’s under FDA’s current proposal. Ask your pharmacy which category they operate under, and cross-check that they’re in good standing with their state board of pharmacy, which is public information you can look up directly rather than take on faith.
Step three: get a real answer on what happens if bulk compounding for your drug ends
This is the question most patients haven’t asked yet, and it’s the most important one. If your compounding pharmacy sources semaglutide or tirzepatide from bulk substances and that pathway closes, do they have a transition plan — a different sourcing method, a different formulation, or a referral to a brand-name alternative — or does your supply simply stop? A pharmacy or telehealth provider that can’t answer this clearly is one you should be actively questioning, not passively trusting for your next several months of treatment.
Step four: know your actual alternatives before you need them
If compounded access does tighten meaningfully for you, it helps to already know the landscape rather than scrambling. Brand-name manufacturer savings programs have expanded access more than most patients realize — both Novo Nordisk and Eli Lilly run direct-to-patient programs (NovoCare and LillyDirect, respectively) that can substantially reduce out-of-pocket cost compared to standard retail pricing, particularly for patients without insurance coverage for weight-loss indications. The oral pill options — Foundayo and oral semaglutide — have also added a lower-friction entry point that didn’t exist a year ago, worth discussing with your prescriber if cost or needle-aversion has been part of why compounded product appealed to you in the first place. We break down how those two compare directly in a separate guide to the full oral GLP-1 lineup.
It’s also worth knowing that the FDA’s proposal explicitly leaves room for bulk compounding to resume if a specific drug lands back on the official drug shortage list — so “compounded access is gone forever” isn’t quite the right framing either. This is a narrowing, not necessarily a permanent closure, and it’s worth staying informed rather than assuming the worst-case outcome is locked in.
Step five: don’t let urgency push you toward a worse option
The most dangerous pattern in this transition isn’t patients staying on legitimate compounded product a bit longer while the rules settle — it’s patients who lose access and, under pressure, turn to unverified online sellers outside any pharmacy relationship entirely. That’s a meaningfully bigger risk than anything discussed above: counterfeit and contaminated product has already been documented circulating through unauthorized channels, in some cases containing substances that have no business anywhere near a GLP-1 drug. If your legitimate access is genuinely disrupted, the right move is calling your prescriber to build a real transition plan — not filling the gap with the first online seller that shows up in an ad.
The bottom line
None of this requires panic, and it doesn’t mean everyone currently on a compounded GLP-1 needs to switch tomorrow. It means getting specific — about your actual product, your pharmacy’s actual regulatory status, and your actual backup plan — before the regulatory ground shifts further under a supply chain a lot of patients have been trusting without asking these questions.
Frequently asked questions
Is it illegal for me to keep taking compounded semaglutide right now?
Not as of this writing — the 503B bulks exclusion is a regulatory proposal that’s moved through public comment, and some compounding remains legal depending on shortage status and whether it’s individualized 503A compounding versus 503B bulk production. This isn’t legal advice specific to your situation; when in doubt, ask your pharmacy directly about their current regulatory status.
Will my compounding pharmacy tell me if they have to stop making my medication?
They’re generally expected to, but proactively asking now — rather than waiting to find out at your next refill — puts you in a much better position to plan ahead.
Are brand-name GLP-1s actually more expensive than compounded versions?
Often yes on list price, but manufacturer savings programs, insurance coverage (which has been expanding, including some recent court rulings favoring coverage), and new oral options have narrowed that gap for many patients compared to a year or two ago. It’s worth getting an actual current quote rather than assuming outdated pricing still applies.
Sources: FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List; Stanford Medicine on compounded GLP-1 safety risks; FDA warning letters to 30 telehealth companies — FiercePharma.